EUVIMEDEUVIMED entdecken
Crossref

[ 177 Lu]Lu-XYIMSR-01: A Novel CAIX-Targeted Radiotherapeutic for Enhanced Treatment of Malignant Glioma

Jing Wang, Chengxue He, Rui Guo, Li Wen, Jinping Tao, Huimao Zhang, HaiFeng Huang, Hua Zhu, Zhi Yang iD, Xianteng Yang iD

Bioconjugate Chemistry · 2025

DOI: 10.1021/acs.bioconjchem.5c00041 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioconjugate Chemistry, 2025. Verfasst von Jing Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, First Hospital of Jilin University, Changchun 130021, China. Hauptthemen laut MEDLINE: Glioma, Radioisotopes, Lutetium, Carbonic Anhydrase IX. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Department of Finance of Jilin Province, Guizhou Science and Technology Department, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Malignant glioma highly expresses carbonic anhydrase IX (CAIX). This study aimed to develop [177Lu]Lu-XYIMSR-01, a small-molecule therapeutic agent CAIX, to assess its potential for treating malignant glioma. [177Lu]Lu-XYIMSR-01 was synthesized by radiolabeling DOTA-XYIMSR-01 with 177Lu. In vitro assays were conducted to evaluate the affinity for U87MG tumor cells. The probe was injected via the tail vein into subcutaneous and orthotopic U87MG models for micro-SPECT/CT imaging. The survival rates of tumor-bearing mice were assessed after [177Lu]Lu-XYIMSR-01 injection by intratumoral in orthotopic models, including untreated controls and those treated with Temozolomide or combination therapy. After purification, the radiochemical yield of [177Lu]Lu-XYIMSR-01 was 86.47 ± 2.42%, with a radiochemical purity (RCP) of 99%. Its cell uptake in U87MG cells was 3.70 ± 0.57 ‰ AD/105 cells, significantly higher than that in HCT116 cells (0.68 ± 0.16 ‰ AD/105 cells, P = 0.001). In the biodistribution study, [177Lu]Lu-XYIMSR-01 uptake in U87MG tumors was 6.19 ± 1.37%ID/g, with a tumor/muscle ratio of 20.14 ± 3.24. In the orthotopic glioma model, local injection combined with Temozolomide significantly improved survival and inhibited tumor growth. The results indicate that [177Lu]Lu-XYIMSR-01 is a promising therapeutic molecular probe for targeting CAIX, and its combination with Temozolomide significantly enhances treatment outcomes for malignant glioma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GliomaRadioisotopesLutetiumCarbonic Anhydrase IXRadiopharmaceuticalsBrain NeoplasmsAntigens, NeoplasmAnimalsHumansMiceCell Line, TumorTissue DistributionTemozolomideMice, Nude

Substanzen

RadioisotopesLutetiumCarbonic Anhydrase IXLutetium-177RadiopharmaceuticalsTemozolomideCA9 protein, humanAntigens, Neoplasm

Autor:innen und Institutionen

  • Department of Radiology, First Hospital of Jilin University, Changchun 130021, China.
  • State Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Beijing Key Laboratory of Carcinogenesis and Translational Research, NMPA Key Laboratory for Research and Evaluation of Radiopharmaceu…
  • Department of Orthopedics, Guizhou Provincial People's Hospital, Guiyang 550002, China.

ORCID-Profile: Zhi Yang, Xianteng Yang

Förderung

  • Department of Finance of Jilin Province
  • Guizhou Science and Technology Department
  • National Natural Science Foundation of China

Zitieren

APA

Wang, J., He, C., Guo, R., Wen, L., Tao, J., Zhang, H., Huang, H., Zhu, H., Yang, Z., & Yang, X. (2025). [ 177 Lu]Lu-XYIMSR-01: A Novel CAIX-Targeted Radiotherapeutic for Enhanced Treatment of Malignant Glioma. Bioconjugate Chemistry. https://doi.org/10.1021/acs.bioconjchem.5c00041

Vancouver

Wang J, He C, Guo R, Wen L, Tao J, Zhang H, et al. [ 177 Lu]Lu-XYIMSR-01: A Novel CAIX-Targeted Radiotherapeutic for Enhanced Treatment of Malignant Glioma. Bioconjugate Chemistry. 2025. doi:10.1021/acs.bioconjchem.5c00041

BibTeX
@article{Wang2025,
  author = {Wang, Jing and He, Chengxue and Guo, Rui and Wen, Li and Tao, Jinping and Zhang, Huimao and Huang, HaiFeng and Zhu, Hua and Yang, Zhi and Yang, Xianteng},
  title = {[ 177 Lu]Lu-XYIMSR-01: A Novel CAIX-Targeted Radiotherapeutic for Enhanced Treatment of Malignant Glioma},
  journal = {Bioconjugate Chemistry},
  year = {2025},
  doi = {10.1021/acs.bioconjchem.5c00041}
}
Kostenlos starten →